Automate Your Wheel Strategy on NVO
With Tiblio's Option Bot, you can configure your own wheel strategy including NVO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol NVO
- Rev/Share 68.2827
- Book/Share 31.2062
- PB 10.4612
- Debt/Equity 0.857
- CurrentRatio 0.7386
- ROIC 0.3875
- MktCap 1449473300888.6833
- FreeCF/Share 16.8361
- PFCF 19.3925
- PE 13.8536
- Debt/Assets 0.2427
- DivYield 0.0322
- ROE 0.8124
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | NVO | HSBC Securities | Buy | Hold | -- | $57 | July 31, 2025 |
| Downgrade | NVO | Barclays | Overweight | Equal Weight | -- | -- | July 30, 2025 |
| Downgrade | NVO | BMO Capital Markets | Outperform | Market Perform | -- | $64 | April 17, 2025 |
| Upgrade | NVO | Kepler | Hold | Buy | -- | -- | March 13, 2025 |
| Downgrade | NVO | Stifel | Buy | Hold | -- | -- | March 3, 2025 |
| Initiation | NVO | Morgan Stanley | -- | Equal Weight | -- | -- | Feb. 12, 2025 |
| Upgrade | NVO | Bernstein | Underperform | Market Perform | -- | -- | Jan. 6, 2025 |
News
Novo Nordisk: Don't Miss Buying This Dip
Published: July 30, 2025 by: Seeking Alpha
Sentiment: Positive
Novo Nordisk's 20%+ price drop since yesterday following a significant downgrade in sales and profit guidance is a great buying opportunity. The stock's forward P/E is at half the stock's five-year average, and with growth catalysts in place, fundamentals could improve too. The launch of NovoCare is showing signs of boosting Wegovy's sales, and the E.U.-U.S. trade deal adds stability for the new CEO.
Read More
Securities Fraud Investigation Into Novo Nordisk A/S (NVO) Continues – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
Published: July 30, 2025 by: Business Wire
Sentiment: Neutral
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz continues its investigation of Novo Nordisk A/S (“Novo Nordisk” or the “Company”) (NYSE: NVO) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON NOVO NORDISK A/S (NVO), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is The Investigation About? On June 23, 2025, Novo Nordisk announced that it was ending its partn.
Read More
Rosen Law Firm Encourages Novo Nordisk A/S Investors to Inquire About Securities Class Action Investigation – NVO
Published: July 30, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Novo Nordisk A/S (NYSE: NVO) resulting from allegations that Novo Nordisk may have issued materially misleading business information to the investing public. So What: If you purchased Novo Nordisk securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangem.
Read More
Can Novo Nordisk's New CEO Stop Rivals From Taking Over the Anti-Obesity Market?
Published: July 30, 2025 by: WSJ
Sentiment: Neutral
The company's first non-Danish leader, Maziar Mike Doustdar, will face a challenging landscape in the U.S.
Read More
Novo Nordisk: After the profit warning what next?
Published: July 30, 2025 by: Proactive Investors
Sentiment: Negative
Shares in Novo Nordisk (NYSE:NVO) are under the spotlight after a surprise profit warning, which, while denting the share price, failed to the wreak the damage some might have feared. That said, the 3.6% fall in the stock piles on the pain for the Ozempic maker, which was formerly Europe's most valuable company.
Read More
Novo Nordisk Stock Got Battered. Think Twice Before Buying the Dip.
Published: July 30, 2025 by: Barrons
Sentiment: Negative
The maker of Ozempic and Wegovy just had its worst day since Black Monday 1987
Read More
Novo Nordisk: Catch That Falling Knife
Published: July 30, 2025 by: Seeking Alpha
Sentiment: Positive
Novo Nordisk's stock has dropped over 20%, but its core business remains strong and diversified, making this an attractive entry point for investors. Despite increased GLP-1 competition and lowered guidance, Novo Nordisk continues to grow, expand its market share, and generate robust cash flow. The company's rare disease and oral semaglutide segments are showing promising growth, with a strong R&D pipeline supporting future expansion.
Read More
Novo Nordisk shares fall further as new CEO faces US challenges
Published: July 30, 2025 by: Reuters
Sentiment: Negative
Shares in Wegovy maker Novo Nordisk continued to slide on Wednesday as analysts warned of persistent competition from copycat drugs in the U.S., a day after a profit warning and the naming of a new CEO prompted investors to wipe $70 billion off the drugmaker's value.
Read More
Novo Nordisk: Massive Overreaction Presents An Opportunity
Published: July 29, 2025 by: Seeking Alpha
Sentiment: Positive
Novo Nordisk's sharp selloff is an overreaction; long-term fundamentals remain solid despite lowered guidance and a sudden CEO change. US market headwinds, competitive pressure from Eli Lilly and telehealth, and regulatory loopholes are weighing on near-term growth. Novo Nordisk boasts a robust pipeline with promising obesity and diabetes drugs, including oral Wegovy and next-generation therapies.
Read More
Novo Nordisk's Downgraded Expectations - What The Market Is (Obviously) Missing
Published: July 29, 2025 by: Seeking Alpha
Sentiment: Negative
Novo Nordisk A/S shares plunged after a Q2 revenue update and 2025 guidance downgrade, despite strong double-digit sales and profit growth. The market is concerned about headwinds for semaglutide (Wegovy/Ozempic), including supply issues, competition, and regulatory risks. Despite the selloff, I believe Novo remains undervalued given its dominant GLP-1 franchise, robust pipeline, and long-term growth potential.
Read More
Wegovy maker Novo's profit warning wipes out $70B in market value after shares plunge 30%
Published: July 29, 2025 by: New York Post
Sentiment: Neutral
Novo, which became Europe's most valuable listed company following the launch of Wegovy in 2021, is now facing a reckoning as it looks to turn things around after the abrupt removal in May of CEO Lars Fruergaard Jorgensen.
Read More
NVO stock: Why did Novo Nordisk shares drop 20% today—and who is Maziar Mike Doustdar?
Published: July 29, 2025 by: Fast Company
Sentiment: Negative
Health-related stocks are not having a good day. First, America's largest health insurance provider, UnitedHealth Group (NYSE: UNH), saw its stock drop more than 4% this morning after the company announced disappointing second-quarter results and a full-year 2025 forecast that concerned investors.
Read More
Don't buy the dip in Novo Nordisk yet, says Mizuho's Jared Holz
Published: July 29, 2025 by: CNBC Television
Sentiment: Negative
Jared Holz, Mizuho health care equity strategist, joins 'Money Movers' to discuss Novo Nordisk sinking on guidance cut and his outlook for the stock.
Read More
Ozempic Maker Novo Nordisk Is Plunging 20%. Time to Sell or Buy More?
Published: July 29, 2025 by: 24/7 Wall Street
Sentiment: Negative
Key Points in This Article: Novo Nordisk's (NVO) operations update reported 18% sales and 29% operating profit growth for H1 2025, but one-off adjustments inflated results.
Read More
Novo Nordisk sinks on guidance cut
Published: July 29, 2025 by: CNBC Television
Sentiment: Negative
CNBC's Angelica Peebles joins 'Squawk on the Street' with the latest details on Novo Nordisk's earnings, why the stock is under pressure, and much more.
Read More
Novo Nordisk Stock Eyes Worst Day Ever on Outlook Cut
Published: July 29, 2025 by: Schaeffers Research
Sentiment: Negative
Pharma giant Novo Nordisk A/S (NYSE:NVO) is plunging 21% to trade at a nearly three-year low of $54.27, after the company's surprise cut to its full-year guidance due to a lower sales outlook for several drugs.
Read More
Ozempic maker stock just collapsed
Published: July 29, 2025 by: Finbold
Sentiment: Negative
Shares of Danish pharmaceutical giant Novo Nordisk (NYSE: NVO), behind the weight-loss drug Wegovy and diabetes medication Ozempic, tumbled on Tuesday after the company slashed its full-year 2025 guidance, triggering a sharp sell-off from investors.
Read More
3 'Wide Moat' SWANs
Published: July 25, 2025 by: Seeking Alpha
Sentiment: Positive
Despite a greedy market, we've found three quality stocks - NVO, RGA, and CP - offering strong value, growth, and reliable dividends. Novo Nordisk leads obesity treatment with strong GLP-1 drugs, a robust pipeline, and a 3.1% yield, trading well below historical P/E. Reinsurance Group of America is an undervalued, financially sound dividend grower with global reach and double-digit earnings growth potential.
Read More
Novo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on It
Published: July 25, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.
Read More
Novo Nordisk (NVO) is a Top-Ranked Momentum Stock: Should You Buy?
Published: July 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Novo Nordisk: Undervalued Despite Strong Growth Trend & Solid Market Share
Published: July 24, 2025 by: Seeking Alpha
Sentiment: Positive
I am bullish on Novo Nordisk due to its 62% global GLP-1 market share and dominant Ozempic sales, supporting long-term leadership. Novo Nordisk's diversified GLP-1 portfolio, including Rybelsus and pending pill versions, positions it well against competitors and broadens its addressable market. Consistent double-digit revenue and profit growth, plus strong Q2 2025 expectations, reflect robust demand and effective cost management.
Read More
Amgen vs. Novo Nordisk: Which Pharma Giant Is the Better Buy?
Published: July 23, 2025 by: Zacks Investment Research
Sentiment: Positive
AMGN's deep pipeline and rare disease expansion may outweigh NVO's GLP-1 dominance and leadership shakeup.
Read More
Here's Why Novo Nordisk (NVO) is a Strong Value Stock
Published: July 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Novo Nordisk: The Market Hasn't Given It Enough Respect
Published: July 23, 2025 by: Seeking Alpha
Sentiment: Negative
Healthcare stocks have lagged the S&P 500, with Novo Nordisk already hit hard by intense competition from Eli Lilly. Despite recent setbacks and a decelerating growth outlook, Novo Nordisk's valuation now reflects steep pessimism, suggesting the downside appears limited. Novo Nordisk's robust brand, R&D, and profit margins provide a significant moat, even as competition in the GLP-1 market intensifies.
Read More
Novo Nordisk's Moat Is Deeper Than You Think
Published: July 22, 2025 by: Seeking Alpha
Sentiment: Positive
Novo Nordisk holds 72% international and 50%+ U.S. market share in GLP-1 treatments, serving 46 million patients globally. Obesity drug sales surged 65% YoY in Q1-FY25, driving total revenue growth of 18% and free cash flow of $1.38 billion. The company projects FY25 free cash flow between $8.14–$9.59 billion, supported by 48.43% EBIT margins and expanding manufacturing capacity.
Read More
Novo Nordisk (NYSE: NVO) Stock Price Prediction and Forecast 2025-2030 (July 2025)
Published: July 21, 2025 by: 24/7 Wall Street
Sentiment: Negative
Among all the weight loss drugs, Ozempic has become a phenomenon. With as much as $17 billion in sales in 2024 and almost $5 billion in the first quarter of 2025, it shows no signs of slowing down, much to the delight of its Danish manufacturer, Novo Nordisk A/S (NYSE: NVO).
Read More
Fangzhou and Novo Nordisk Signed Collaboration Memorandum to Establish a New Ecosystem for Health Management
Published: July 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
Fangzhou Inc., a leader in Internet healthcare solutions, signed a Memorandum of Understanding with Novo Nordisk, a leading global healthcare company.
Read More
Can Wegovy & Ozempic Drive Another Strong Quarter for Novo Nordisk?
Published: July 18, 2025 by: Zacks Investment Research
Sentiment: Positive
Wegovy and Ozempic drive 66% of NVO's Q1 revenues - investors eye Q2 sales ahead of results on Aug. 6.
Read More
3 Ridiculously Discounted Growth Stocks to Buy Now
Published: July 16, 2025 by: 24/7 Wall Street
Sentiment: Positive
Key Points in This Article: Buying beaten-down stocks allows investors to purchase high-quality companies at bargain prices, capitalizing on market overreactions.
Read More
Novo Nordisk Plunges 20% YTD: How Should Investors Play the Stock?
Published: July 15, 2025 by: Zacks Investment Research
Sentiment: Negative
NVO shares fall 19.9% year to date amid weak CagriSema data, CEO exit and rising pressure from rivals in obesity care.
Read More
About Novo Nordisk A/S (NVO)
- IPO Date 1981-04-30
- Website https://www.novonordisk.com
- Industry Drug Manufacturers - General
- CEO Lars Fruergaard Jorgensen
- Employees 77406